SPR719
Based on 4 publication(s) in Google Scholar
SPR719 (VXc-486) is an orally active gyrase B inhibitor, with bactericidal activity. SPR719 potently inhibits multiple agent-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis, with MICs of 0.03 to 0.30 μg/ml and 0.08 to 5.48 μg/ml, respectively. SPR719 is promising for research of lung disease caused by non-tuberculous mycobacteria (NTM).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.39%
- CAS 番号: 1384984-18-2
- 分子式: C21H25FN6O3
- 分子量:428.46
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Topoisomerase アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
gyrase B[1]
体外実験
SPR719 inhibits M. tuberculosis replication in macrophages with a MIC range of 0.125-0.25 μg/mL[1][2].
IC50 (μg/ml) of SPR719 for indicated isolate in macrophages[1]
| Compound | H37Ra | CDC1551 |
| SPR719 | 0.012 | 0.115 |